|

Donanemab placebo Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2/3: 1

Top Sponsors

  • Banner Health1

Indications

  • Autosomal Dominant Alzheimers Disease1
  • Alzheimers Disease1
  • Alzheimer's Disease1
  • Early-Onset Alzheimer Disease1

Other1 trial

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.